Kymab

Kymab's main business is the research and development using the fully human antibody technology platform KymouseTM. Kymab utilizes its proprietary Kymouse platform to discover, develop, and commercialize human therapeutic monoclonal antibodies for the treatment of human diseases. Its platform captures the diversity of the B lymphocyte component of the human immune system and generates biologics based on human antibodies targeting both clinically validated drug targets and novel targets.